The Pneumonia Etiology Research for Child Health (PERCH) study will characterize the etiologic distribution of pathogens that are causing severe pneumonia among children under five years of age who have been hospitalized for their illness in seven …

This article, published in Clinical Infectious Diseases, details the Pneumonia Etiology Research for Child Health (PERCH) project, which is a seven-country, standardized, comprehensive evaluation of the etiologic agents causing severe …

This report examines the epidemiological evidence on the burden and distribution of pneumonia and assesses current levels of treatment and prevention. The report aims to raise awareness about this neglected disease and its causes, and serve as a …

Published in the journal Pediatrics, this study aims to determine the population impact of pneumococcal conjugate vaccine (PCV) on pneumococcal-related diseases, including pneumonia and otitis media by measuring annual rates of medical visits for …

Published in the Pediatric Infectious Disease Journal, this study evaluates the impact of the introduction and routine use of seven valent pneumococcal conjugate vaccine on the epidemiology of invasive pneumococcal disease within the …

This article, published in Archives of Pediatrics and Adolescent Medicine, estimates the potential effect of the acceleration of administration of the first dose of pneumococcal conjugate vaccine from two months to six weeks of age. The …

Children younger than two years have the highest rates of invasive pneumococcal disease and play an important role in its transmission. In the United States, seven pneumococcal serotypes cause approximately 80 percent of invasive disease …

Pneumococcal conjugate vaccines are highly effective in preventing invasive disease in infants and young children, with favorable safety and immunogenicity profiles. These pediatric vaccines have also shown efficacy in reducing cases of non-invasive …

This article, published in Vaccine, reviews the history of pneumococcal vaccines with a focus on the first heptavalent conjugated pneumococcal vaccine (PCV7), which was first licensed in the United States in 2000, followed by many other countries. …

This article, published in the journal Vaccine, reviews the incidence of vaccine-serotype invasive pneumococcal disease and other pneumococcal-associated respiratory tract diseases following the routine use of the seven-valent pneumococcal conjugate …

The efficacy of pneumococcal conjugate vaccines (PCV) and their remarkable success in operational use in North America challenge us to define the burden of pneumococcal disease and the likely benefits of PCV use in developing countries. …

This report includes the US Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices recommended pneumococcal vaccination schedule for infants at ages 2, 4, 6, and 12 to 15 months. This report also includes a …

This special edition of the Bulletin of the World Health Organization focuses on the prevention and control of childhood pneumonia. It highlights research on the many aspects that drive this deadly disease and the progress now …

This report, published by the US Centers for Disease Control and Prevention (CDC), summarizes recommendations approved by the CDC's Advisory Committee on Immunization Practices (ACIP) on February 24, 2010, for the use of 13-valent …

Published in the CDC's Morbidity and Mortality Weekly Report, this article provides recommendations on the use of pneumococcal polysaccharide vaccines to prevent pneumococcal disease.

This article, published in Vaccine, reviews background information on the diagnosis and treatment of pneumonia and pneumococcal disease in children, as well as the history and benefits of vaccination against pneumococcal disease. The authors …

This website provides information on Pfizer's (formerly Wyeth's) 13-valent pneumococcal conjugate vaccine, including usage and safety information.

Several vaccines that have come to market, including the rotavirus, pneumococcal conjugate, and human papillomavirus vaccines, have the potential to bring large public health benefits to developing countries. This eight-page policy brief explains …

This study, published in the Journal of American Medical Association, evaluates the projected health and economic impact of pneumococcal conjugate vaccination of healthy US infants and young children through a cost-effectiveness analysis based …

The authors of this article, published in Vaccine, determined the impact and cost-effectiveness of pneumococcal and rotavirus vaccination programs among children younge than five years of age in Uganda from the public health system perspective. They …

This article, published in Vaccine, emphasizes the importance of capsular polysaccharide vaccines for preventing disease caused by Neisseria meningitidis and Streptococcus pneumoniae in Africa, reiterating that these vaccines have been proven safe …

The Network studied the characteristics of invasive pneumococcal infections in six hospitals in India over four years, in patients with suspected pneumonia (3686), pyogenic meningitis (1107), septicaemia (257), or localised …

This fact sheet describes how PATH developed a low-cost and straightforward technology for protecting aluminum-adjuvanted liquid vaccines from the irreversible damage that results from freezing. Many current vaccines of importance to global …

This fact sheet provides a snapshot of PATH's programs that tackle the leading causes of childhood illness and death: pneumonia, diarrheal disease, and malaria. It profiles PATH's work on new and innovative vaccines, medicines, diagnostics, and …

These pre-formatted PubMed searches will retrieve journal citations and available abstracts that address disease burden, vaccine efficacy and benefits, model programs and cost issues in Asian, African, and Latin American countries.  Documents …